

275/LG/SE/NOV/2024/GBSL

November 14, 2024

To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code : <u>509079</u> To National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Symbol : <u>GUFICBIO</u>

Subject: Outcome of the Board of Directors Meeting held on Thursday, November 14, 2024

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. November 14, 2024, has, inter-alia, considered and approved the following matters:

- 1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2024 along with the Limited Review Report thereon in terms of provisions of Regulation 33 of SEBI Listing Regulations.
- 2. Appointment of Mr. Akshya Kumar Mahapatra (DIN: 08362446) as an Additional Director (Non-Executive Independent Director) of the Company, for an initial term of 5 years with effect from November 14, 2024, subject to approval of the shareholders.

Further, it is hereby confirmed that Mr. Mahapatra is not debarred from holding the office of Director by virtue of any order passed by Securities and Exchange Board of India (SEBI) or any other such authority.

The details as required for the abovementioned appointment of Director under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is annexed herewith as **"Annexure – B"**.

3. Reconstitution of Audit Committee ("AC"), Nomination & Remuneration Committee ("NRC"), Corporate Social Responsibility Committee ("CSR") and Risk Management Committee ("RMC") due to expiry of the second term of Mr. Gopal Daptari (DIN: 07660662), Independent Director of the Company, who is also a Chairperson of AC and CSR and a Member of NRC and RMC, effective as on the closing of business hours on November 23, 2024. The new composition of the said Committees with effect from November 24, 2024 shall be as follows:



| Name of the Committee | Composition | Category |
|--|---|---|
| Audit Committee | Mr. Kamal Kishore Seth – Chairperson | Non-Executive & Independent Director |
| | Dr. Anu Aurora – Member | Non-Executive & Independent Director |
| | Mr. Akshya Kumar Mahapatra – Member | Non-Executive & Independent Director |
| | Mr. Jayesh Choksi – Member | Executive Director |
| Nomination & Remuneration Committee | Dr. Anu Aurora – Chairperson | Non-Executive & Independent Director |
| | Mr. Kamal Kishore Seth – Member | Non-Executive & Independent Director |
| | Mr. Akshya Kumar Mahapatra – Member | Non-Executive & Independent Director |
| Corporate Social Responsibility Committee | Mr. Jayesh Choksi – Chairperson | Executive Director |
| | Dr. Anu S. Aurora – Member | Non-Executive & Independent Director |
| | Mr. Pranav Choksi – Member | Executive Director |
| Risk Management Committee | Mr. Jayesh Choksi – Chairperson | Executive Director |
| | Mr. Pranav Choksi – Member | Executive Director |
| | Dr. Anu Aurora – Member | Non-Executive & Independent Director |
| | Mr. Devkinandan Roonghta – Member | Chief Financial Officer |
| | Mr. Nagesh Yarrabathina – Member | Chief Operating Officer |



The meeting of the Board of Directors commenced at 5:45 p.m. and concluded at 07:15 p.m.

Kindly take the same on your record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited

Ami Shah Company Secretary & Compliance Officer Membership No. A39579

Encl.: As above



<u>Annexure – B</u>

| Particulars | Mr. Akshya Kumar Mahapatra (DIN: 08362446) | |
|--|--|--|
| Reason for change | Appointment as an Additional Director (Non-Executive Independent Director) of the Company | |
| Date of appointment/ cessation | Appointment with effect from November 14, 2024 | |
| Term of appointment/ re- appointment | Appointed for an initial term of 5 years with effect from November 14, 2024, subject to approval of the shareholders. | |
| Brief profile (in case of appointment) | Mr. Akshya Kumar Mahapatra holds an MBA degree with a specialization in Marketing from Behrampur University, Orissa, a B.Sc. from Utkal University, and a Post Graduate Diploma in Foreign Trade Management from the World Trade Centre. With over 31 years of experience in the pharmaceutical industry, Mr. Mahapatra has worked with several renowned companies, including Glenmark Pharmaceuticals Limited, Claris Life-Sciences Limited, Merck India Ltd, and Wockhardt Ltd. In recent years, he has held key leadership positions, serving as the Managing Director of Celon Laboratories Limited, Chief Business Officer at API Holdings Limited – PharmEasy, and is currently the Founder and Director of Aleafiaa Pharmaceuticals Private Limited. | |
| | | |
| | Mr. Mahapatra is known for his exceptional ability to transform underperforming businesses into profitable ventures. His extensive experience encompasses leading large teams and driving the creation of new business verticals in areas such as Critical Care, Oncology, Nephrology, Respiratory Medicine and Nutrition. As a visionary leader, he combines business acumen, operational proficiency and technical expertise to drive growth and ensure long-term success. | |
| Disclosure of relationships between directors (in case of appointment of director) | Mr. Akshya Kumar Mahapatra is not related to any Director of the Company. | |